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Temporal changes in inflammatory mitochondria-
enriched microRNAs following traumatic brain injury 
and effects of miR-146a nanoparticle delivery
Wang-Xia Wang1, 2, 3, *, #, Paresh Prajapati2, 4, #, Hemendra J. Vekaria2, 4, Malinda Spry2, 4, 
Amber L. Cloud2, 4, Patrick G. Sullivan2, 4, Joe E. Springer2, 4, *
Abstract  
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate post-transcriptional 
gene expression and contribute to all aspects of cellular function. We previously reported 
that the activities of several mitochondria-enriched miRNAs regulating inflammation (i.e., 
miR-142-3p, miR-142-5p, and miR-146a) are altered in the hippocampus at 3–12 hours 
following a severe traumatic brain injury. In the present study, we investigated the temporal 
expression profile of these inflammatory miRNAs in mitochondria and cytosol fractions at 
more chronic post-injury times following severe controlled cortical impact injury in rats. In 
addition, several inflammatory genes were analyzed in the cytosol fractions. The analysis 
showed that while elevated levels were observed in cytoplasm, the mitochondria-enriched 
miRNAs, miR-142-3p and miR-142-5p continued to be significantly reduced in mitochondria 
from injured hippocampi for at least 3 days and returned to near normal levels at 7 days 
post-injury. Although not statistically significant, miR-146a also remained at reduced levels 
for up to 3 days following controlled cortical impact injury, and recovered by 7 days. In 
contrast, miRNAs that are not enriched in mitochondria, including miR-124a, miR-150, 
miR-19b, miR-155, and miR-223 were either increased or demonstrated no change in their 
levels in mitochondrial fractions for 7 days. The one exception was that miR-223 levels were 
reduced in mitochondria at 1 day following injury. No major alterations were observed 
in sham operated animals. This temporal pattern was unique to mitochondria-enriched 
miRNAs and correlated with injury-induced changes in mitochondrial bioenergetics as 
well as expression levels of several inflammatory markers. These observations suggested a 
potential compartmental re-distribution of the mitochondria-enriched inflammatory miRNAs 
and may reflect an intracellular mechanism by which specific miRNAs regulate injury-
induced inflammatory signaling. To test this, we utilized a novel peptide-based nanoparticle 
strategy for in vitro and in vivo delivery of a miR-146a mimic as a potential therapeutic 
strategy for targeting nuclear factor-kappaB inflammatory modulators in the injured brain. 
Nanoparticle delivery of miR-146a to BV-2 or SH-SY5Y cells significantly reduced expression 
of TNF receptor-associated factor 6 (TRAF6) and interleukin-1 receptor-associated kinase 1 
(IRAK1), two important modulators of the nuclear factor-kappaB (NF-κB) pro-inflammatory 
pathway. Moreover, injections of miR-146a containing nanoparticles into the brain 
immediately following controlled cortical impact injury significantly reduced hippocampal 
TNF receptor-associated factor 6 and interleukin-1 receptor-associated kinase 1 levels. Taken 
together, our studies demonstrate the subcellular alteration of inflammatory miRNAs after 
traumatic brain injury and establish proof of principle that nanoparticle delivery of miR-146a 
has therapeutic potential for modulating pro-inflammatory effectors in the injured brain. All 
of the studies performed were approved by the University of Kentucky Institutional Animal 
Care and Usage Committee (IACUC protocol # 2014-1300) on August 17, 2017.
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Introduction 
Traumatic brain injury (TBI) elicits a rapid and pronounced 
neuroinflammatory response propagated, in part, by resident 
microglia as well as circulating monocytes that differentiate 
into macrophages along a continuum ranging from 
cytotoxic pro-inflammatory to reparative anti-inflammatory 
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phenotypes. These cells have been consistently linked with 
pro-inflammatory signaling processes underlying chronic 
degenerative changes after TBI (Ziebell and Morganti-
Kossmann, 2010; Kumar and Loane, 2012; Woodcock and 
Morganti-Kossmann, 2013). The expression of reparative 
myeloid cells peaks at approximately one week following injury 
and then declines, while the pro-inflammatory phenotype may 
persist for months to years (Ziebell and Morganti-Kossmann, 
2010; Kumar and Loane, 2012; Johnson et al.,  2013; 
Woodcock and Morganti-Kossmann, 2013; Kumar et al., 2015). 
This differential expression pattern favoring prolonged pro-
inflammation limits tissue repair and is associated with poor 
functional outcomes. Therefore, strategies that effectively 
l imit detrimental pro-inflammatory responses, while 
maintaining the reparative potential of macrophages, have 
clear therapeutic potential (Ziebell and Morganti-Kossmann, 
2010; Kumar and Loane, 2012; Woodcock and Morganti-
Kossmann, 2013). In support of this, experimental approaches 
that mitigate pro-inflammatory signaling after severe TBI can 
significantly reduce tissue pathology and promote functional 
recovery (Lloyd et al., 2008; Hsieh et al., 2014; Bachstetter et 
al., 2015; Morganti et al., 2015). However, identifying tools 
that shift these myeloid effectors towards a reparative bias 
with a high degree of specificity and efficacy has been very 
limited. One novel strategy with high translational potential 
is the use of nanoparticle technologies to deliver microRNAs 
(miRNAs) targeting genes that regulate inflammatory signaling 
(O’Neill et al., 2011; Contreras and Rao, 2012; O’Connell et al., 
2012).
MiRNAs are evolutionally conserved non-coding short RNA 
molecules that bind recognition elements in messenger RNA 
(mRNA) and fine tune post-transcriptional gene expression 
(Bartel, 2004; Huntzinger and Izaurralde, 2011). MiRNAs 
regulate all aspects of cellular function, and disruption of 
miRNA activity contributes to many disease states including 
neurodegeneration (Calin and Croce, 2006; Nelson et 
al., 2008; Liu and Xu, 2011; Hata, 2013). MiRNA-based 
therapeutic approaches have been tested and several 
are currently in clinical trials targeting hepatitis C, type 2 
diabetes, and several cancer types (Rupaimoole and Slack, 
2017). Therefore, the ability of miRNAs to regulate expression 
of genes contributing to TBI-related neuroinflammatory 
signaling makes them attractive therapeutic candidates. Using 
mouse and rat models, we and others have reported that a 
number of miRNAs are altered in cortex and hippocampus 
following TBI (Redell et al., 2009; Hu et al., 2012; Liu et al., 
2014; Sabirzhanov et al., 2014; Wang et al., 2015, 2017; 
Harrison et al., 2017; Kumar et al., 2017). The studies from 
our lab are the first to demonstrate that a subset of miRNAs 
regulating cellular inflammatory activities (e.g., miR-146a) is 
enriched in brain mitochondria fractions (Wang et al., 2015, 
2017). We also reported that levels of these miRNAs display a 
compartmental shift from the mitochondria to the cytosol as 
early as 3–12 hours following TBI (Wang et al., 2015, 2017), 
which corresponds to the temporal loss in mitochondrial 
function after acute TBI (Sullivan et al., 1998, 2007; Singh et 
al., 2006). These observations suggest an interaction between 
mitochondrial function and miRNA-mediated inflammatory 
signaling at early time points following TBI.
MiR-146a plays a significant role in regulating levels of 
inflammatory cytokines and related signaling events in a 
manner that favors expression of the reparative macrophage 
phenotype (Cui and Liu, 2015). However, the relationship 
between miRNA changes and inflammatory signaling in 
the hippocampus beyond 12 hours following TBI is not 
known. Moreover, strategies that modify miRNA signaling to 
effectively promote expression of the reparative macrophage 
phenotype are lacking. Therefore, the aim of this study was 
to quantify changes of select miRNAs and inflammatory 
genes isolated from the hippocampus at different time points 
following severe TBI. In addition, we tested the ability of miR-
146a nanoparticle delivery to target the nuclear factor-kappaB 
(NF-κB) modulators TNF receptor-associated factor 6 (TRAF6) 
and interleukin-1 receptor-associated kinase 1 (IRAK1) in vitro 
as well as in vivo after severe TBI. 
Materials and Methods
Animals and TBI procedures
All of the studies performed were approved by the University 
of Kentucky Institutional Animal Care and Usage Committee 
( IACUC protocol  # 2014-1300) on August 17,  2017. 
Additionally, the Division of Laboratory Animal Resources 
at the University is accredited by the Association for the 
Assessment and Accreditation for Laboratory Animal Care, 
International (AAALAC, International) and all experiments 
were performed with its guidelines. All animal experiments 
are in compliance with ARRIVE guidelines and experiments 
are carried out in accordance with the National Institutes 
of Health Guide for the Care and Use of Laboratory Animals 
(NIH Publication No. 85-23, revised 1996). Thirty young 
adult male (7–10 weeks old) Sprague-Dawley rats weighing 
~250 g (Charles River Laboratories, Wilmington, MA, USA) 
were acclimated for 7 days prior to experimentation. Rats 
were allowed free access to food/water and housed in a 
temperature-controlled room on a 12-hour light/dark cycle. 
The surgical and brain injury procedures performed in this 
study followed our previously published protocols (Sullivan 
et al., 1999; Wang et al., 2015). The controlled cortical 
impact (CCI) injury is a well-established brain injury model 
utilized by numerous researchers and, as such, allows for 
comparison of outcomes across studies (Dixon et al., 1991). 
Briefly, experimental rats were anesthetized with a dose 
of 4% isoflurane (Covetrus, Portland, ME, USA) via a nose 
cone and were positioned in a stereotaxic frame (David 
Kopf, Tujunga, CA, USA). The surgical and CCI procedure was 
conducted under sterile conditions and continued supplied 
dose of 2.5% isoflurane throughout the procedure. The core 
body temperature of the experimental rats was kept at 37°C 
during the procedures and the post-surgical/CCI recovery 
period. An incision was made along the midline in a rostra-
caudal orientation to expose the skull. A 6-mm craniotomy 
was then created lateral to center between bregma and 
lambda. The brain injury was performed by driving a 5 mm 
diameter rod tip at 3.5 m/s velocity to compress the cortex 
to a depth of 2.0 mm using a pneumatically controlled 
impacting device (Precision Systems and Instrumentation, 
Fairfax Station, VA, USA). This procedure resulted in a severe 
injury consistent with previous studies (Baldwin et al., 1997; 
Davis et al., 2008; Gilmer et al., 2009) and characterized by 
physical damage to the cortex and the presence of neuronal 
damage to the underlying hippocampus. Following injury, 
surgical absorbable hemostat was placed in the craniotomy 
and a plastic disc adhered to the skull to cover and stabilize 
the craniotomy site. Sham animals received identical exposure 
to the surgical procedures, but without brain injury. The 
surgeries were conducted at the same time of day, 2 days 
apart with three CCI and two sham operations performed at 
each time. Animals (total n = 6 per group for CCI, n = 4 per 
group for sham surgery) were euthanatized with CO2 at 1, 3, 
or 7 days following injury and the ipsilateral and contralateral 
hippocampi were rapidly removed for isolation of the 
mitochondria and cytosolic fractions.
Cytosolic and mitochondrial fractionation
For mitochondrial bioenergetics and the miRNA and mRNA 
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expression studies, the mitochondria and cytosol fractions 
were obtained from the hippocampus following a previously 
described Ficoll density gradient procedure (Pandya et 
al., 2009). Briefly, harvested hippocampal tissue was 
homogenized in pre-cooled mitochondrial isolation buffer (215 
mM mannitol, 75 mM sucrose, 0.1% bovine serum albumin 
(BSA), 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 1 mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid (EGTA); pH adjusted to 7.2 with 
KOH). The homogenate was then centrifuged at 1300 × g for 
3 minutes to remove tissue debris and nuclei. The resulting 
supernatant was then subjected to a centrifugation at 13,000 
× g for 10 minutes to obtain crude mitochondrial pellets and 
the supernatant was saved as cytosol (CT) fraction. The re-
suspended crude mitochondria sample was then placed into 
a nitrogen cell disruption chamber for 10 minutes (1200 psi) 
to rupture and release synaptosomal mitochondria (Brown 
et al., 2004). The crude mitochondria fraction was then 
laid over a discontinuous Ficoll gradient (7.5% + 10%) and 
further separated by centrifugation using a SW 55Ti rotors 
at 100,000 × g for 30 minutes. The mitochondria pellet (MT) 
was rinsed in mitochondrial isolation buffer in the absence of 
EGTA and centrifuged at 10,000 × g at 4°C for 10 minutes and 
resuspended in the same buffer to achieve a concentration of 
~10 mg/mL. The protein content of the various fractions was 
analyzed using BCA protein assay kit (ThermoFisher, Waltham, 
MA USA). 
 
Mitochondria bioenergetics
Mitochondrial bioenergetics were assessed using the Seahorse 
Biosciences XFe24 Flux Analyzer (Agilent Technologies 
[Santa Clara, CA]; RRID:SCR_013575) using a procedure 
developed in our lab (Sauerbeck et al., 2011; Pandya et 
al., 2016; Hubbard et al., 2018). In these experiments, 
rotenone, oligomycin, and trifluoromethoxy carbonylcyanide 
phenylhydrazone, 2-[2-[4-(tr if luoromethoxy)phenyl]
hydrazinylidene]-propanedinitrile (FCCP) were purchased 
from Biomol (Plymouth Meeting, PA, USA). All other reagents 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Briefly, 3.5 µg protein equivalent of isolated mitochondria 
were suspended in respiration buffer (RB) (125 mM KCl, 2 mM 
MgCl2, 0.1% BSA, 20 mM HEPES and 2.5 mM KH2PO4, adjusted 
pH 7.2). The combination of substrates/inhibitors/uncoupler 
were prepared in RB and 75 µL of each injected as pyruvate 
+ malate + adenosine diphosphate (ADP), oligomycin, FCCP, 
and rotenone + succinate sequentially through ports A–D at 
the final concentrations of 5 mM pyruvate, 2.5 mM malate, 1 
mM ADP, 1 µg/mL oligomycin, 4 µM FCCP, 0.1 µM rotenone, 
and 10 mM succinate. ADP driven complex I mediated 
coupled respiration (State III), ATPase locked leaky respiration 
(State IV), complex I driven maximum uncoupled respiration 
(State VCI), and complex II-driven maximum respiration (State 
VCII) were determined with each subsequent injection. The 
results are presented as oxygen consumption rate (OCR) and 
expressed as pmol of oxygen consumed per minute.
TaqMan single-tube miRNA RT-qPCR
Isolation of total hippocampal tissue RNA from the cytosolic 
and mitochondrial fractions and TaqMan single-tube RT-qPCR 
(ThermoFisher) of select miRNA were performed as previously 
reported (Wang et al., 2008, 2015). Selected miRNAs for 
analysis included miR-146a (Assay ID: 000468), miR-142-
3p (Assay ID: 000464), miR-142-5p (Assay ID: 002248), miR-
155 (Assay ID: 002571), miR-150 (Assay ID: 000473), miR-223 
(Assay ID: 002295), miR-124a (Assay ID: 001182), and miR-
19b (Assay ID: 000396). Each miRNA analysis was performed 
in technical triplicates of either contralateral or ipsilateral 
hippocampi for a total of 6 TBI and 4 sham biological replicates 
from each time point (n = 6 TBI, n = 4 sham). The raw cycle 
threshold (CT) values were determined using QuantStudioTM 
Real-Time PCR Software with automatic baseline and threshold 
(ThermoFisher). Overall miRNA levels following TBI or sham 
surgery in the cytoplasmic and mitochondrial fractions at each 
time point were calculated using formula RQ = 2–(Ct(Ipsi)–Ct(Contra)) 
(Table 1) comparing the ipsilateral injured side or sham surgery 
side relative to the uninjured contralateral side or no surgery 
side (RQ: relative quantity). To evaluate the net change of 
miRNA enrichment in mitochondria, the following formula was 
used: RQ = 2–(Ct(Mito)–Ct(Cyto)) comparing the mitochondria fraction 
to cytoplasmic fraction of the same brain side. The calculation 
method followed the instructions detailed in the “Guide to 
Performing Relative Quantitation of Gene Expression Using 
Real-Time Quantitative PCR” (Applied Biosystems). 
 
Gene expression analysis using TaqMan low density array 
panel
A customized TaqMan low density array (TLDA) qRT-PCR panel 
in an 8 × 48 gene array format (ThermoFisher) was employed 
to analyze gene expression in cytosolic fractions from the 
injured ipsilateral hippocampi relative to the uninjured 
contralateral side. Forty-seven genes including a group of 
inflammatory-related marker genes (Gensel et al., 2017) 
and an internal control ‘house-keeping’ gene (18S) were 
selected for the custom array. The list of genes and their assay 
IDs are provided in Additional Table 1. Total cytosolic RNA 
(500 ng) was subjected to first-strand cDNA synthesis using 
SuperScriptTM III First-Strand Synthesis System (ThermoFisher). 
The resulting cDNA from each sample was then combined 
with TaqMan Universal PCR Master Mix (No AmpErase UNG, 
ThermoFisher) and loaded into each port of the TLDA cards 
following manufacturer’s instructions. Quantitative real-time 
PCR was performed with a QuantStudioTM 7 Real-Time PCR 
System (ThermoFisher) using the manufacturer’s standard 
program (hold 2 minutes at 50°C, followed by 10 minutes at 
95°C, then 40 cycles of 15 seconds at 95°C and 1 minute at 
60°C).
 
TLDA data processing
Raw qPCR CT (cycle threshold) values from the TLDA card were 
first determined using QuantStudioTM Real-Time PCR Software 
(ThermoFisher) with automatic baseline and threshold. PCR 
data that failed software-defined QC and those CT values equal 
to or more than 35 were considered as undetectable and were 
given a value of 35. The CT value of 18S ribosomal RNA was 
used to obtain ΔCT values of a given sample and the whole 
dataset was then further normalized using the Global Mean 
Normalization method (Mestdagh et al., 2009) to minimize the 
technical variability among array sets. The comparative ∆∆CT 
method was used to calculate relative gene expression levels. 
Mean ΔΔCT values and standard deviations were calculated 
following the “Guide to Performing Relative Quantitation of 
Gene Expression Using Real-Time Quantitative PCR” (Applied 
Biosystems (2008)). The effect of TBI on each gene in the TLDA 
card was expressed as fold change in cytosolic fractions from 
the ipsilateral hippocampus relative to uninjured contralateral 
side.
Cell permeable peptide-delivery of miRNA mimic in cell 
cultures
Cell culture experiments were conducted to document 
the ability of a mellitin-derived cell permeable peptide 
(p5RHH) to introduce Cy5-labeled miR-146a or scrambled 
control (Integrated DNA Technologies, Skokie, IL, USA) 
to BV-2 (kind gift from Dr. Linda van Eldik of University of 
Kentucky) and SH-SY5H (Cat# CRL-2266, ATCC, Manassas, 
VA, USA, RRID:CVCL_0019) cells. The p5RHH peptide 
Research Article
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(VLTTGLPALISWIRRRHRRHC) was synthesized by NeoScientific 
(Neobiolabs, Cambridge, MA, USA) and a stock of 10 mM 
was prepared using protease and nuclease free water, 
aliquoted and stored at –80°C. A total of 3 × 105 cells were 
seeded into 12-well plates and maintained for 24 hours 
in standard cell culture conditions prior to transfection. 
Nanoparticle complexes were prepared at a ratio of 200:1 
(molar ratio of p5RHH:miR-146a mimic) with 20 nM miR-
146a using procedures described previously (Hou, 2014). 
The p5RHH+miR-146a nanoparticles were then incubated 
with BV-2 and SH-SY5Y cells for 24 hours. Additional plated 
cells were incubated with Cy5-labeled miR-146a only or 
transfected using Lipofectamine RNAiMAX (ThermoFisher) to 
assess p5RHH + miR-146a transfection efficiency. Cells were 
visualized and photographed using a Nikon C2+ confocal 
microscope (Nikon Inc, Melville, NY, USA) and then washed 
with PBS and harvested for RNA analysis or Western blot 
analysis with either TRAF6 or Actin antibodies. 
Peptide-delivery of miRNA mimic to rat brain following CCI
Animals were subjected to a CCI injury and randomly assigned 
to receive an intrahippocampal injection of p5RHH + miR-
146a mimic or scrambled RNA control nanoparticles to test 
in vivo effect of the miR-146a mimic on TRAF6 and IRAK1. 
Immediately following injury, a Hamilton syringe with a 
33-gauge Nanofil (WPI, Sarasota, FL, USA) blunt needle was 
slowly lowered in the dorsal hippocampus ipsilateral to the 
injury side using stereotaxic coordinates (Paxinos and Watson, 
2013) –3.3 mm from bregma, 2.4 mm from midline, and 2.8 
mm ventral. The needle was left in place for 1 minute before 
injecting a total of 0.5 µL of p5RHH:miR-146a nanoparticles 
(ratio of 200:1, 40 nM miR-146a) at a rate of 10 nL/s using 
a WPI Ultramicropump III connected to a WPI MICRO2T 
SMARTouch controller (WPI, Sarasota, FL, USA). The needle 
was left in place for an additional 2 minutes, slowly withdrawn, 
and the craniotomy site and overlying skin treated and closed 
with sutures. The animals were then euthanatized with CO2 at 
48 hours after injection and the hippocampus removed rapidly 
and the dorsal hippocampal tissue used to analyze TRAF6 and 
IRAK1 gene expression using single-tube TaqMan assays (Wang 
et al., 2015) and western blotting for TRAF6.
Protein isolation and western blot analysis
Protein isolation and Western blot analysis were performed 
using standard techniques routinely performed in our lab 
(Wang et al., 2015). Briefly, RIPA buffer (Cat# R0278; Sigma) 
was used to lyse proteins of rat hippocampal tissue, as well as 
total cellular protein in transfected cells. Protein concentrations 
were determined using BCA protein assay (Cat# 23227, Pierce 
Biotechnology, Rockford, IL, USA). For Western blotting, equal 
amounts of protein (10–20 µg) were loaded on 4–16% Mini-
PROTEAN® TGXTM gels (Cat# 456-1106, Bio-Rad, Hercules, 
CA, USA) and run at 0.03 A. The gels were then transblotted 
onto polyvinylidene fluoride membranes (Cat# 1620177, Bio-
Rad) and non-specific binding sites blocked by incubating 
the membrane with 5% nonfat milk for 1–2 hours. The blots 
were then incubated overnight with primary antibody at 4°C. 
Primary antibodies used in this study included anti-TRAF6 
(1:1000 dilution; rabbit, Cat# ab33915; Abcam, Cambridge, 
MA, USA) and anti-actin (1:2000, rabbit, Cat# A5060; Sigma). 
After 3–4 rinses following primary antibody incubation, 
blots were incubated with goat anti-rabbit peroxidase-
conjugated secondary antibody (Jackson ImmunoResearch 
laboratories, Inc. West Grove, Pennsylvania, USA) or IRDye® 
800 goat anti-rabbit IgG (1:20,000, Cat# 925-68070, LI-COR, 
Lincoln, Nebraska, USA) for 1 hour at room temperature. The 
immunoreactive signals were visualized using SuperSignalTM 
West Pico PLUS Chemiluminescent Substrate (Pierce 
Biotechnology) or using Odyssey CLx (LI-COR, Lincoln). 
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 
8.0.2 (GraphPad Software Inc., San Diego, CA, USA) Animal 
numbers were powered according to published experimental 
data and anticipated effect sizes. One-way analysis of variance 
and Student’s t-test (two-tailed) were applied to evaluate 
mean differences (bioenergetics and miRNA, mRNA single-
tube assay data) when appropriate. A Student’s t-test was 
used to evaluate the difference of the mean fold change 
of inflammatory responsive genes between the ipsilateral 
and contralateral cytoplasm of qPCR data and western blot 
densitometry data. Data are expressed as the mean ± SD 
and a P value less than 0.05 was considered as statistically 
significant. 
Table 1 ｜ Changes in miRNA levels in cytoplasmic fractions of hippocampal tissue following TBI and in sham-operated control animals
miRNA
1 d 3 d 7 d
Fold (range) P-value Fold (range) P-value Fold (range) P-value
TBI miR-124 0.93 (0.67–1.27) 0.625 0.99 (0.87–1.13) 0.919 1.03 (0.73–1.45) 0.885
miR-142-3p 2.24 (1.61–3.11) 0.001 3.49 (1.97–6.17) 0.001 0.93 (0.70–1.24) 0.886
miR-142-5p 2.62 (2.05–3.35) 0.0001 3.41 (2.47–4.70) 0.0002 0.94 (0.72–1.22) 0.878
miR-146a 1.55 (0.98–2.47) 0.148 1.93 (1.09–3.42) 0.078 0.93 (0.54–1.58) 0.852
miR-150 0.87 (0.59–1.29) 0.541 0.88 (0.66–1.19) 0.678 0.96 (0.87–1.06) 0.548
miR-155 11.54 (6.3–21.3) 0.00017 6.18 (3.92–9.72) 0.020 1.15 (0.73–1.81) 0.828
miR-223 15.0 (9.9–22.8) 0.000002 3.92 (2.07–7.42) 0.003 0.66 (0.32–1.35) 0.538
miR-19b 1.31 (1.06–1.63) 0.072 1.33 (1.04–1.72) 0.028 0.83 (0.70–0.97) 0.318
Sham miR-124 0.90 (0.70–1.17) 0.711 0.86 (0.7–1.05) 0.213 0.88 (0.27–1.77) 0.482
miR-142-3p 0.89 (0.82–1.29) 0.897 1.23 (0.86–1.76) 0.329 1.50 (0.83–2.71) 0.573
miR-142-5p 0.87 (0.70–1.07) 0.485 1.28 (0.68–2.42) 0.520 1.36 (0.67–2.76) 0.701
miR-146a 1.05 (0.74–1.48) 0.865 0.96 (0.47–1.98) 0.941 1.76 (1.25–2.47) 0.495
miR-150 0.87 (0.73–1.04) 0.581 0.91 (0.60–1.37) 0.719 1.07 (0.96–1.19) 0.740
miR-155 1.89 (1.27–2.81) 0.202 1.22 (0.44–3.40) 0.735 3.04 (1.58–5.84) 0.355
miR-223 1.67 (1.15–2.43) 0.095 1.61 (0.71–1.82) 0.494 2.55 (1.82–3.57) 0.357
miR-19b 1.00 (0.87–1.15) 0.999 0.85 (0.61–1.17) 0.379 1.39 (1.00–1.94) 0.372
Levels of miRNAs were calculated using the formula: fold change = 2–(Ct(Ipsi)–Ct(Contra)) comparing the ipsilateral injured/sham-operated side of the brain relative 
to that of the uninjured/no operated contralateral side of the same animal. Data represent the mean value of the six biological replicates for traumatic brain 
injury (TBI) and four biological replicates for sham, and the P-values were generated using two-tailed Student’s t-test (GraphPad 8.0.2). The fold change range 
is shown in parentheses. Significantly different expressed miRNAs are highlighted in red (P < 0.05). 1, 3, or 7 days indicates the tissue harvesting time following 
controlled cortical impact or sham surgery.
[Downloaded free from http://www.nrronline.org on Tuesday, December 29, 2020, IP: 250.216.147.196]
518  ｜NEURAL REGENERATION RESEARCH｜Vol 16｜No.3｜March 2021
Results
Mitochondria bioenergetics following TBI
The post-injury bioenergetic profile of total mitochondria 
isolated from the hippocampus revealed significant changes in 
state-dependent oxygen consumption rates (OCR) over time 
(Figure 1). The OCR significantly decreased in all four tested 
respiration states (P < 0.01, for State III, State VCI, and State 
VCII, respectively; P < 0.05 for State IV) in mitochondria isolated 
from the ipsilateral hippocampus at 1 day following CCI 
relative to intact contralateral side (Figure 1A). At 3 days post 
CCI, OCR in mitochondria from the ipsilateral hippocampus 
continued to be significantly decreased in State IV and 
State VCII (P < 0.05), with near significant decreased levels 
in State III (P = 0.058) compared to the contralateral side. 
By 1 week post-injury, there were no significant differences 
in any respiration state in mitochondria from the injured 
hippocampus relative to contralateral side. Sham-surgery did 
not result in any significant changes in bioenergetics across all 
three time points (Figure 1B).
Alteration of the association of mitochondria-enriched 
miRNAs following TBI
We reported previously that levels of miR-146a, miR-142-
3p, and miR-142-5p are highly enriched in the mitochondria 
compared to cytosol (Wang et al., 2015). We also found 
that the levels of these mitochondria-enriched miRNAs 
are decreased in the mitochondrial fraction at early times 
following TBI (3 and 12 hours), and that all three miRNAs 
increased in cytoplasmic fractions at the same time points 
(Wang et al., 2015, 2017). In the present study, we further 
investigated levels of these miRNAs at extended times up to 
7 days following TBI (Figure 2). When miRNA levels in the 
mitochondrial fraction are normalized to that of cytoplasmic 
fraction, it provides a relative measure of mitochondrial 
enrichment. The enrichment of miR-142-3p and miR-142-
5p significantly decreased (P = 0.050 and 0.002, respectively) 
at 1 day post TBI in mitochondria from the injured ipsilateral 
hippocampus compared to the uninjured contralateral 
hippocampus (Figure 2A). The mitochondrial enrichment of 
these two miRNAs remained significantly lower for up to 3 
days (P < 0.01) and returned to near normal levels at 7 days 
post-injury. The levels of another mitochondria-enriched 
miRNA, miR-146a trended lower at 1 day in the mitochondrial 
fraction following TBI with a similar pattern being observed at 
3 days. However, by 7 days post-injury, miR-146a levels in the 
mitochondrial fraction were found to be significantly elevated 
(P = 0.033; Figure 2A). 
The levels of several non-mitochondria-enriched miRNAs 
also exhibited changes over time following TBI with different 
trends (Figure 2B). MiR-124a, miR-150, miR19b and a known 
TBI-responsive miRNA miR-155 were either increased (such 
as miR-124a, miR-155, miR-19b) or not significantly altered 
(miR-150) in mitochondria at any time examined following 
TBI. One exception was miR-223 (Figure 2B), which is also a 
TBI-responsive miRNA that showed significantly decreased 
levels in mitochondria at 1 day after TBI (P < 0.01). However, 
by 7 days post-injury, the levels of miR-223 were significantly 
elevated (P < 0.05) in mitochondria isolated from the 
injured hippocampus. No major changes in any of the above 
mentioned miRNAs were observed between the ipsilateral 
and contralateral hippocampal mitochondria isolated from the 
group of sham operated animals (Additional Figure 1).
Interestingly, while levels of the mitochondria-enriched 
miRNAs miR-142-3p and miR-142-5p were reduced in 
mitochondria at 1 and 3 days following TBI, their levels in 
cytoplasmic fractions significantly increased (P < 0.01; Table 
1). By 7 days following TBI, the levels of both miR-142-3p 
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Figure 1 ｜ Temporal assessment of State III, IV, and VCI and VCII 
mitochondrial respiration rates in hippocampal mitochondria after severe 
TBI (A) or sham-surgery (B). 
Animals (total n = 6 per group for CCI, n = 4 per group for sham surgery) were 
euthanatized at 1, 3, or 7 days following injury and the ipsilateral (Ipsi) and 
contralateral (Contra) hippocampi were rapidly removed for isolation of the 
mitochondria. Mitochondrial bioenergetics was assessed using the Seahorse 
Biosciences XFe24 Flux Analyzer. Data are expressed as the mean ± SD. The 
difference between the ipsilateral and the contralateral hippocampi was 
evaluated using one-way analysis of variance and Student’s t-test. *P < 0.05, 
**P < 0.01, ***P < 0.001. OCR: Oxygen consumption rate; TBI: traumatic brain 
injury. 
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Figure 2 ｜ Profile of mitochondria-enrichment of miRNAs following 
traumatic brain injury. 
Animals (total n = 6 per group) were euthanatized at 1, 3, or 7 days following 
injury and the ipsilateral (Ipsi) and contralateral (Contra) hippocampi were 
rapidly removed for isolation of the mitochondria (Mito) and cytosolic (Cyto) 
fractions. The fractions were then subjected to RNA isolation and miRNA 
analysis. The level of mitochondria-enrichment of a miRNA expressed as 
relative quantity (RQ) was calculated using the formula RQ = 2–(Ct(Mito)–Ct(Cyto)) 
where mitochondrial and cytoplasmic fractions were isolated from the same 
tissue. (A) Mitochondria-enriched miRNAs. (B) Other miRNAs. Data are 
expressed as the mean ± SD. The difference between the ipsilateral and the 
contralateral hippocampi was evaluated using one-way analysis of variance 
and Student’s t-test. *P < 0.05, **P < 0.01.
and miR-142-5p in the cytoplasmic fraction had returned to 
normal. A similar trending pattern was observed for miR-146a. 
Finally, levels of two TBI-responsive miRNAs, miRNA miR-155 
and miR-223 were significantly elevated in the cytoplasm at 1 
and 3 days post-injury and returned to normal levels by 7 days 
(see levels and P values in Table 1).
Inflammatory gene expression at different time points 
following TBI 
A customized TLDA was used to analyze the expression 
of selected inflammatory-related genes in hippocampal 
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Table 2 ｜ Response of inflammatory-related genes in hippocampus following TBI
Gene symbol
1 d 3 d 7 d
Fold (range) P-value Fold (range) P-value Fold (range) P-value
Anti-inflammatory Arg1 0.37 (0.26–0.53) 0.005 0.54 (0.39–0.75) 0.025 1.29 (0.81–2.04) 0.340
Ccl22 0.69 (0.3–1.62) 0.550 0.35 (0.30–0.42) 0.151 1.08 (0.64–1.82) 0.799
Epas1 0.61 (0.47–0.78) 0.001 0.85 (0.63–1.14) 0.301 1.21(0.88–1.66) 0.271
Il4 0.28 (0.12–0.61) 0.072 0.57 (0.27–1.23) 0.285 1.71 (0.73–4.01) 0.351
Pparg 0.61 (0.44–0.83) 0.032 0.52 (0.24–1.11) 0.178 1.01 (0.75–1.37) 0.952
Sphk1 6.10 (3.4–10.9) 0.004 1.49 (1.03–2.16) 0.390 0.83 (0.69–1.01) 0.275
Stat6 0.66 (0.51–0.86) 0.013 0.92 (0.78–1.09) 0.514 1.22 (0.95–1.56) 0.155
Tgfb1 1.53 (1.2–1.94) 0.006 2.28 (1.85–2.82) 0 0.60 (0.34–1.07) 0.282
Tgm2 2.40 (1.78–3.24) 0.011 1.17 (0.99–1.39) 0.220 1.31 (0.81–2.11) 0.442
Pro-inflammatory Ccr2 10.67 (6.3–18.0) 0.004 4.93 (3.54–6.88) 0.007 0.65 (0.21–2.00) 0.505
Ccl2 160 (85.5–299.8) 0.002 15.43 (8.16–29.2) 0.001 0.47 (0.17–1.27) 0.367
Ccr7 0.47 (0.3–0.74) 0.079 0.74 (0.45–1.21) 0.361 1.54 (1.14–2.07) 0.242
Cd86 0.87 (0.47–1.59) 0.646 2.51 (1.91–3.31) 0.007 0.50 (0.28–0.92) 0.290
Il12a 0.30 (0.21–0.42) 0.001 0.55 (0.45–0.67) 0 1.26 (0.94–1.67) 0.396
Il12b 0.36 (0.24–0.54) 0.010 0.44 (0.30–0.64) 0.057 0.76 (0.51–1.14) 0.235
Il1b 9.46 (6.55–13.7) 0.001 1.58 (1.23–2.04) 0.053 0.50 (0.27–0.94) 0.458
Il6 0.78 (0.51–1.18) 0.392 0.76 (0.48–1.22) 0.512 1.13 (0.77–1.68) 0.737
Nos2 2.12 (0.47–9.6) 0.395 0.51 (0.43–0.60) 0.098 0.47 (0.12–1.80) 0.702
Stat1 0.89 (0.7–1.14) 0.377 0.98 (0.81–1.18) 0.720 1.15 (0.87–1.52) 0.314
Aif1 1.48 (0.9–1.45) 0.510 3.13 (2.11–4.63) 0.004 0.54 (0.24–1.19) 0.313
Nlrp3 1.04 (0.77–1.4) 0.801 2.17 (1.82–2.59) 0.001 0.85 (0.54–1.32) 0.590
Itgam 1.56 (1.23–1.98) 0.018 3.07 (2.52–3.74) 0.001 0.71 (0.41–1.21) 0.419
A TLDA card consisting of selected inflammatory responsive genes was used to assess mRNA expression levels in hippocampal cytoplasm obtained from each 
time points following traumatic brain injury (TBI). Gene expression levels were calculated using formula: fold change = 2–(Ct(Ipsi)–Ct(Contra)) comparing the ipsilateral 
injured side of the brain relative to the uninjured contralateral side. Data represent the mean value of 4 biological replicates, and the P values were generated 
using two-tailed Student’s t-tests. The fold change range is shown in parentheses. Significantly different (P < 0.05) expression genes are highlighted in red for 
increased expression and in green for decreased expression. The 1, 3, and 7 days indicate the tissue harvesting time following controlled cortical impact.
cytoplasm. In general, alterations in gene expression were 
found to be most active at 1 day following TBI (Table 2). 
By 3 days following TBI, the number and levels of genes 
significantly altered were less than that at 1 day, especially 
with respect to anti-inflammatory genes (Table 2). Among 
the tested genes, there was only one anti-inflammatory gene, 
Tgfb1, which remained elevated at 3 days post-injury. Among 
the pro-inflammatory genes examined, the chemokine (C-C 
motif) ligand 2 (CCL2, also called monocyte chemoattractant 
protein 1, MCP1) appeared to have the greatest change 
and was significantly elevated in the injured ipsilateral 
hippocampus compared to uninjured side by 160- and 15-
fold respectively at 1 and 3 days post TBI (P < 0.05; Table 2). 
By 7 days following TBI, CCL2 levels returned to control values 
and we did not observe any significant differences in any of 
the other genes in the panel at 7 days between the ipsilateral 
injured and contralateral sides.
Effect of miR-146a nanoparticle delivery to BV-2 and 
SH-SY5Y cells
MiR-146a targets TRAF6 and IRAK1, two effectors that are 
important regulators on the NF-κB pathway (Taganov et al., 
2006). Given our previous observations demonstrating a 
differential expression of miR-146a at early hours following 
TBI (Wang et al., 2015, 2017), we selected this anti-
inflammatory miRNA for the peptide-based nanoparticle 
delivery studies. We first tested the effects of the peptide/
miR-146a nanoparticle delivery system using the mouse 
microglial BV-2 and human neuroblastoma SH-SY5Y cell 
line. These two cell lines were incubated with p5RHH + miR-
146a-Cy5 mimic or scrambled control nanoparticles for 48 
hours. Additional cell culture wells were incubated with miR-
146a-Cy5 mimic (or scrambled control) without any carrier 
or in the presence of Lipofectamine RNAiMAX, the latter 
of which served as a positive transfection control. Confocal 
microscopy demonstrated effective transfection of miR-
146a-Cy5 in both the BV-2 (Figure 3A) and SH-SY5Y cells 
(Additional Figure 2) using p5RHH peptide or Lipofectamine, 
while no fluorescent signal was observed in the cells where 
transfection carrier agent was not used. These observations 
document the necessity of using cell permeable carrier 
molecules to ensure cellular delivery of Cy5-labeled miR-146a. 
Western blot analysis confirmed the biological activity of miR-
146a in p5RHH peptide and Lipofectamine transfected cells 
as reflected by a significant decrease in TRAF6 protein levels 
(P = 0.0005 and 0.013, respectively; Figure 3B and C). These 
experiments suggest that the p5RHH + miR-146a nanoparticle 
platform effectively delivered miR-146a mimic and down-
regulated its validated target TRAF6. 
Effect of miR-146a delivery to the injured rat hippocampus  
The p5RHH peptide was then used to deliver miR-146a 
mimic or scrambled control to the rat hippocampus following 
severe TBI. The miR-146a mimic-nanoparticle complex 
was injected into the dorsal hippocampus immediately 
following a severe CCI and animals sacrificed 48 hours later. 
Hippocampi were then harvested for analysis of TRAF6 
and IRAK1 gene and protein (TRAF6) expression. RT-qPCR 
revealed a significant reduction in IRAK1 (P = 0.048) and 
TRAF6 (P = 0.036) mRNA levels following miR-146a delivery in 
comparison to scrambled control demonstrating the efficacy 
of the nanoparticle delivery system (Figure 4A). Importantly, 
Western blot analysis demonstrated that TRAF6 protein levels 
were also decreased in the hippocampus of animals receiving 
p5RHH + miR-146a nanoparticles (Figure 4B).  
Discussion
Our previous studies reported that several mitochondria-
enriched miRNAs regulating inflammation including miR-142-
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3p, miR-142-5p, and miR-146a are altered in the hippocampus 
following a severe traumatic brain injury (Wang et al., 2015, 
2017). Specifically, the levels of these miRNAs were reduced 
significantly in mitochondria at 3–12 hours following TBI 
(Wang et al., 2015, 2017). We now demonstrate that the 
levels of these same miRNAs continue to be reduced in 
the hippocampal mitochondria for at least 3 days following 
TBI, with a concomitant increase in expression levels in the 
cytosol. Interestingly, the reduction in mitochondria-enriched 
miRNAs coincided with decreased mitochondrial bioenergetics 
at the same time points following injury. The results of 
these experiments suggest a potential time-dependent 
compartmental re-distribution of mitochondria-enriched 
miRNAs that is related to TBI-induced loss of mitochondrial 
bioenergetics. We further demonstrate the utilization of 
a novel cell-penetrating peptide nanoparticle system for 
delivery of miR-146a for targeting modulators of NF-κB pro-
inflammatory signaling pathway in vitro and in vivo.
We suggested previously that mitochondria and miRNA 
interactions may play a role in miRNA cellular function related 
to inflammation in the injured brain (Wang et al., 2015, 2017). 
This was based on our observations that levels of miR-146a, 
miR-142-3p and miR-142-5p were significantly decreased in 
the mitochondrial fraction and increased in the cytoplasmic 
fraction at early time points post TBI (Wang et al., 2015). We 
hypothesized that this compartmental shift may represent a 
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Figure 3 ｜ In vitro delivery of mellitin-derived cell permeable peptide 
(p5RHH)-based miR-146a nanoparticles to cultured BV-2 cells. 
Confocal microscopy graph of miR-146a and scramble control transfections 
(scale bars: 10 µm) (A) and the western blot analysis of TNF receptor-
associated factor 6 (TRAF6) in the transfected cells (B). Densitometry 
quantification of the western blot analysis from 4 independent transfection 
experiments (C, n = 4). Pre-seeded BV-2 cells were incubated either with 
miR-146a or scramble mimic/p5RHH-nanoparticle complexes or miR-146a or 
scramble mimic/Lipofectamine, or without carrier for 24 hours and the cells 
were visualized and photographed using a Nikon C2+ confocal microscope 
and then washed with PBS and harvested for RNA analysis or western blot 
analysis. The densitometry readout of TRAF6 protein signal was normalized 
on that of actin signal in the same protein sample. Data are expressed as 
the mean ± SD. The difference between miR-146a and scramble mimics was 
evaluated using Student’s t-test. *P < 0.05, ***P < 0.001. 
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Figure 4 ｜ In vivo delivery of miR-146a mimic using mellitin-derived cell 
permeable peptide (p5RHH) effectively reduced levels of TRAF6 and IRAK1 
mRNAs and protein levels. 
Animals were subjected to controlled cortical impact injury (n = 6) and 
randomly assigned to receive an intrahippocampal injection of p5RHH + miR-
146a mimic (n = 3) or scrambled RNA control (n = 3). The animals were then 
euthanatized at 48 hours after injection and the hippocampi removed for 
protein and RNA isolation and analysis. (A) TRAF6 and IRAK1 mRNA levels 
determined by RT-qPCR following TBI and nanoparticle injections. Data 
are expressed as the mean ± SD. The difference between miR-146a and 
scramble mimics was evaluated using Student’s t-test. *P < 0.05. (B) Western 
blot analysis for TRAF6 using hippocampal tissues that were injected with 
either miR-146a or scrambled control mimic. IRAK1: Interleukin-1 receptor-
associated kinase 1; TRAF6: TNF receptor-associated factor 6.
translocation of mitochondria-enriched miRNAs in response 
to cellular stressors (e.g., TBI) that impact mitochondrial 
function. We now show that this compartmental shift is still 
evident up to 3 days following TBI for miR-142-3p and miR-
142-5p in hippocampal tissue, and returns to normal levels by 
7 days. Although not statistically significant, alterations in miR-
146a showed a trend similar to miR-142-3p and miR-142-5p.
It has been well described that TBI elicits a rapid and 
significant loss of mitochondrial function in the hippocampus 
and is a key factor in determining cell survival and recovery 
(Sullivan et al., 1998; Singh et al., 2006). In our current 
study, mitochondrial bioenergetics in the hippocampus were 
significantly compromised for at least 3 days following TBI and 
recovered by 7 days post injury. Interestingly, we observed 
that changes in the expression patterns of the mitochondria-
enriched, inflammatory miRNAs (miR-142-3p, miR-142-
5p, and miR-146a) were highly correlated with the loss in 
mitochondria bioenergetics. Mitochondria can be considered 
as ‘first-responders’ to cellular demands and stressors and can 
trigger various signaling pathways involving gene regulation, 
in which miRNAs play a critical role. Therefore, we postulate 
that mitochondria function may determine the subcellular 
localization and function of these mitochondria-enriched 
miRNAs. Future studies are needed to understand the 
correlation of translocation of these mitochondria-enriched, 
inflammatory miRNAs with mitochondrial bioenergetics and 
its functional impact on the inflammatory response following 
TBI. 
Our miRNA and gene expression studies indicate that 
alterations of selected inflammatory related miRNAs and 
mRNAs peaked at 1 day and their activities remained elevated 
at 3 days. The activities were then reduced to control levels 
at 1 week following TBI. The inflammatory gene expression 
activity observed in this study is consistent with previous 
reports (Morganti-Kossmann et al., 2002; Semple et al., 
2010; Ziebell and Morganti-Kossmann, 2010; Morganti et al., 
2016) and may provide the basis for designing miRNA-based 
interventional strategies targeting acute times following TBI. 
For example, the neuroinflammatory response following TBI 
is characterized by a prolonged period of pro-inflammation 
persisting for months to years after the injury (Johnson 
et al., 2013). However, there also exists a reparative anti-
inflammatory phase that is only present for acute time points 
following TBI (Jin et al., 2012; Hsieh et al., 2013; Kumar et 
al., 2016). Therefore, sustaining a balance of inflammatory 
responses that maintains expression of the reparative phase 
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will be essential to promoting tissue survival and recovery. 
We found that miR-146a levels increased in cytoplasm initially, 
but then returned to control levels by 7 days post-injury. 
These observations are intriguing for at least two reasons. 
First, miR-146a plays a significant role in regulating the 
production of certain pro-inflammatory cytokines by targeting 
two adaptor proteins TRAF6 and IRAK1 that function upstream 
of the NF-κB signaling pathway (Liu et al., 2017). Second, 
miR-146a expression is actually regulated by activation 
of the NF-κB pathway (Taganov 2006). Thus, miR-146a is 
activated by and also acts as a negative feedback regulator 
of NF-κB signaling (Figure 5), which may enable a fine-tune 
control of the inflammatory response. Taken together, it is 
postulated that the transient expression of anti-inflammatory 
reparative signaling may be related to the downregulation 
of miR-146a through NF-κB. While the mechanisms by 
which miR-146a modulates inflammatory signaling in the 
injured brain are currently not known, these observations 
prompted us to test whether nanoparticle delivery of miR-
146a can serve as a therapeutic strategy for modulating the 
neuroinflammatory response following TBI. Specifically, we 
employed a cell-permeable peptide p5RHH to deliver miR-
146a mimic to cultured cell lines and also following TBI. The 
p5RHH cell-permeable peptide forms a non-immunogenic 
nanoparticle complex with small inhibitory RNA molecules 
and has been shown to be an effective delivery platform (Hou 
et al., 2013a; Hou et al., 2013b). Our data demonstrated that 
p5RHH effectively delivered miR-146a mimic and reduced 
the expression levels of TRAF6 and IRAK1 in vitro and in vivo. 
The results of these studies are encouraging as they establish 
a proof of principle that this novel nanoparticle delivery 
approach has therapeutic potential for modulating pro-
inflammatory effectors in the injured brain.
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